Assessment of biopsy-proven liver fibrosis by two-dimensional shear wave elastography: An individual patient data-based meta-analysis

Eva Herrmann, Victor de Lédinghen, Christophe Cassinotto, Winnie C.W. Chu, Vivian Y.F. Leung, Giovanna Ferraioli, Carlo Filice, Laurent Castera, Valérie Vilgrain, Maxime Ronot, Jérôme Dumortier, Aymeric Guibal, Stanislas Pol, Jonel Trebicka, Christian Jansen, Christian Strassburg, Rongqin Zheng, Jian Zheng, Sven Francque, Thomas VanwolleghemLuisa Vonghia, Emanuel K. Manesis, Pavlos Zoumpoulis, Ioan Sporea, Maja Thiele, Aleksander Krag, Claude Cohen-Bacrie, Aline Criton, Joel Gay, Thomas Deffieux, Mireen Friedrich-Rust

Research output: Contribution to journalArticle

55 Citations (Scopus)

Abstract

Two-dimensional shear wave elastography (2D-SWE) has proven to be efficient for the evaluation of liver fibrosis in small to moderate-sized clinical trials. We aimed at running a larger-scale meta-analysis of individual data. Centers which have worked with Aixplorer ultrasound equipment were contacted to share their data. Retrospective statistical analysis used direct and paired receiver operating characteristic and area under the receiver operating characteristic curve (AUROC) analyses, accounting for random effects. Data on both 2D-SWE and liver biopsy were available for 1,134 patients from 13 sites, as well as on successful transient elastography in 665 patients. Most patients had chronic hepatitis C (n = 379), hepatitis B (n = 400), or nonalcoholic fatty liver disease (n = 156). AUROCs of 2D-SWE in patients with hepatitis C, hepatitis B, and nonalcoholic fatty liver disease were 86.3%, 90.6%, and 85.5% for diagnosing significant fibrosis and 92.9%, 95.5%, and 91.7% for diagnosing cirrhosis, respectively. The AUROC of 2D-SWE was 0.022-0.084 (95% confidence interval) larger than the AUROC of transient elastography for diagnosing significant fibrosis (P = 0.001) and 0.003-0.034 for diagnosing cirrhosis (P = 0.022) in all patients. This difference was strongest in hepatitis B patients. Conclusion: 2D-SWE has good to excellent performance for the noninvasive staging of liver fibrosis in patients with hepatitis B; further prospective studies are needed for head-to-head comparison between 2D-SWE and other imaging modalities to establish disease-specific appropriate cutoff points for assessment of fibrosis stage. (Hepatology 2018;67:260-272).

Original languageEnglish
Pages (from-to)260-272
Number of pages13
JournalHepatology
Volume67
Issue number1
DOIs
Publication statusPublished - Jan 1 2018

Fingerprint

Elasticity Imaging Techniques
Liver Cirrhosis
Meta-Analysis
Biopsy
Hepatitis B
Fibrosis
ROC Curve
Chronic Hepatitis C
Gastroenterology
Hepatitis C
Clinical Trials
Prospective Studies
Confidence Intervals
Equipment and Supplies
Liver

ASJC Scopus subject areas

  • Hepatology

Cite this

Herrmann, E., de Lédinghen, V., Cassinotto, C., Chu, W. C. W., Leung, V. Y. F., Ferraioli, G., ... Friedrich-Rust, M. (2018). Assessment of biopsy-proven liver fibrosis by two-dimensional shear wave elastography: An individual patient data-based meta-analysis. Hepatology, 67(1), 260-272. https://doi.org/10.1002/hep.29179

Assessment of biopsy-proven liver fibrosis by two-dimensional shear wave elastography : An individual patient data-based meta-analysis. / Herrmann, Eva; de Lédinghen, Victor; Cassinotto, Christophe; Chu, Winnie C.W.; Leung, Vivian Y.F.; Ferraioli, Giovanna; Filice, Carlo; Castera, Laurent; Vilgrain, Valérie; Ronot, Maxime; Dumortier, Jérôme; Guibal, Aymeric; Pol, Stanislas; Trebicka, Jonel; Jansen, Christian; Strassburg, Christian; Zheng, Rongqin; Zheng, Jian; Francque, Sven; Vanwolleghem, Thomas; Vonghia, Luisa; Manesis, Emanuel K.; Zoumpoulis, Pavlos; Sporea, Ioan; Thiele, Maja; Krag, Aleksander; Cohen-Bacrie, Claude; Criton, Aline; Gay, Joel; Deffieux, Thomas; Friedrich-Rust, Mireen.

In: Hepatology, Vol. 67, No. 1, 01.01.2018, p. 260-272.

Research output: Contribution to journalArticle

Herrmann, E, de Lédinghen, V, Cassinotto, C, Chu, WCW, Leung, VYF, Ferraioli, G, Filice, C, Castera, L, Vilgrain, V, Ronot, M, Dumortier, J, Guibal, A, Pol, S, Trebicka, J, Jansen, C, Strassburg, C, Zheng, R, Zheng, J, Francque, S, Vanwolleghem, T, Vonghia, L, Manesis, EK, Zoumpoulis, P, Sporea, I, Thiele, M, Krag, A, Cohen-Bacrie, C, Criton, A, Gay, J, Deffieux, T & Friedrich-Rust, M 2018, 'Assessment of biopsy-proven liver fibrosis by two-dimensional shear wave elastography: An individual patient data-based meta-analysis', Hepatology, vol. 67, no. 1, pp. 260-272. https://doi.org/10.1002/hep.29179
Herrmann, Eva ; de Lédinghen, Victor ; Cassinotto, Christophe ; Chu, Winnie C.W. ; Leung, Vivian Y.F. ; Ferraioli, Giovanna ; Filice, Carlo ; Castera, Laurent ; Vilgrain, Valérie ; Ronot, Maxime ; Dumortier, Jérôme ; Guibal, Aymeric ; Pol, Stanislas ; Trebicka, Jonel ; Jansen, Christian ; Strassburg, Christian ; Zheng, Rongqin ; Zheng, Jian ; Francque, Sven ; Vanwolleghem, Thomas ; Vonghia, Luisa ; Manesis, Emanuel K. ; Zoumpoulis, Pavlos ; Sporea, Ioan ; Thiele, Maja ; Krag, Aleksander ; Cohen-Bacrie, Claude ; Criton, Aline ; Gay, Joel ; Deffieux, Thomas ; Friedrich-Rust, Mireen. / Assessment of biopsy-proven liver fibrosis by two-dimensional shear wave elastography : An individual patient data-based meta-analysis. In: Hepatology. 2018 ; Vol. 67, No. 1. pp. 260-272.
@article{e792723fb26546ca8d0c696a78a5b93d,
title = "Assessment of biopsy-proven liver fibrosis by two-dimensional shear wave elastography: An individual patient data-based meta-analysis",
abstract = "Two-dimensional shear wave elastography (2D-SWE) has proven to be efficient for the evaluation of liver fibrosis in small to moderate-sized clinical trials. We aimed at running a larger-scale meta-analysis of individual data. Centers which have worked with Aixplorer ultrasound equipment were contacted to share their data. Retrospective statistical analysis used direct and paired receiver operating characteristic and area under the receiver operating characteristic curve (AUROC) analyses, accounting for random effects. Data on both 2D-SWE and liver biopsy were available for 1,134 patients from 13 sites, as well as on successful transient elastography in 665 patients. Most patients had chronic hepatitis C (n = 379), hepatitis B (n = 400), or nonalcoholic fatty liver disease (n = 156). AUROCs of 2D-SWE in patients with hepatitis C, hepatitis B, and nonalcoholic fatty liver disease were 86.3{\%}, 90.6{\%}, and 85.5{\%} for diagnosing significant fibrosis and 92.9{\%}, 95.5{\%}, and 91.7{\%} for diagnosing cirrhosis, respectively. The AUROC of 2D-SWE was 0.022-0.084 (95{\%} confidence interval) larger than the AUROC of transient elastography for diagnosing significant fibrosis (P = 0.001) and 0.003-0.034 for diagnosing cirrhosis (P = 0.022) in all patients. This difference was strongest in hepatitis B patients. Conclusion: 2D-SWE has good to excellent performance for the noninvasive staging of liver fibrosis in patients with hepatitis B; further prospective studies are needed for head-to-head comparison between 2D-SWE and other imaging modalities to establish disease-specific appropriate cutoff points for assessment of fibrosis stage. (Hepatology 2018;67:260-272).",
author = "Eva Herrmann and {de L{\'e}dinghen}, Victor and Christophe Cassinotto and Chu, {Winnie C.W.} and Leung, {Vivian Y.F.} and Giovanna Ferraioli and Carlo Filice and Laurent Castera and Val{\'e}rie Vilgrain and Maxime Ronot and J{\'e}r{\^o}me Dumortier and Aymeric Guibal and Stanislas Pol and Jonel Trebicka and Christian Jansen and Christian Strassburg and Rongqin Zheng and Jian Zheng and Sven Francque and Thomas Vanwolleghem and Luisa Vonghia and Manesis, {Emanuel K.} and Pavlos Zoumpoulis and Ioan Sporea and Maja Thiele and Aleksander Krag and Claude Cohen-Bacrie and Aline Criton and Joel Gay and Thomas Deffieux and Mireen Friedrich-Rust",
year = "2018",
month = "1",
day = "1",
doi = "10.1002/hep.29179",
language = "English",
volume = "67",
pages = "260--272",
journal = "Hepatology",
issn = "0270-9139",
publisher = "John Wiley and Sons Inc.",
number = "1",

}

TY - JOUR

T1 - Assessment of biopsy-proven liver fibrosis by two-dimensional shear wave elastography

T2 - An individual patient data-based meta-analysis

AU - Herrmann, Eva

AU - de Lédinghen, Victor

AU - Cassinotto, Christophe

AU - Chu, Winnie C.W.

AU - Leung, Vivian Y.F.

AU - Ferraioli, Giovanna

AU - Filice, Carlo

AU - Castera, Laurent

AU - Vilgrain, Valérie

AU - Ronot, Maxime

AU - Dumortier, Jérôme

AU - Guibal, Aymeric

AU - Pol, Stanislas

AU - Trebicka, Jonel

AU - Jansen, Christian

AU - Strassburg, Christian

AU - Zheng, Rongqin

AU - Zheng, Jian

AU - Francque, Sven

AU - Vanwolleghem, Thomas

AU - Vonghia, Luisa

AU - Manesis, Emanuel K.

AU - Zoumpoulis, Pavlos

AU - Sporea, Ioan

AU - Thiele, Maja

AU - Krag, Aleksander

AU - Cohen-Bacrie, Claude

AU - Criton, Aline

AU - Gay, Joel

AU - Deffieux, Thomas

AU - Friedrich-Rust, Mireen

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Two-dimensional shear wave elastography (2D-SWE) has proven to be efficient for the evaluation of liver fibrosis in small to moderate-sized clinical trials. We aimed at running a larger-scale meta-analysis of individual data. Centers which have worked with Aixplorer ultrasound equipment were contacted to share their data. Retrospective statistical analysis used direct and paired receiver operating characteristic and area under the receiver operating characteristic curve (AUROC) analyses, accounting for random effects. Data on both 2D-SWE and liver biopsy were available for 1,134 patients from 13 sites, as well as on successful transient elastography in 665 patients. Most patients had chronic hepatitis C (n = 379), hepatitis B (n = 400), or nonalcoholic fatty liver disease (n = 156). AUROCs of 2D-SWE in patients with hepatitis C, hepatitis B, and nonalcoholic fatty liver disease were 86.3%, 90.6%, and 85.5% for diagnosing significant fibrosis and 92.9%, 95.5%, and 91.7% for diagnosing cirrhosis, respectively. The AUROC of 2D-SWE was 0.022-0.084 (95% confidence interval) larger than the AUROC of transient elastography for diagnosing significant fibrosis (P = 0.001) and 0.003-0.034 for diagnosing cirrhosis (P = 0.022) in all patients. This difference was strongest in hepatitis B patients. Conclusion: 2D-SWE has good to excellent performance for the noninvasive staging of liver fibrosis in patients with hepatitis B; further prospective studies are needed for head-to-head comparison between 2D-SWE and other imaging modalities to establish disease-specific appropriate cutoff points for assessment of fibrosis stage. (Hepatology 2018;67:260-272).

AB - Two-dimensional shear wave elastography (2D-SWE) has proven to be efficient for the evaluation of liver fibrosis in small to moderate-sized clinical trials. We aimed at running a larger-scale meta-analysis of individual data. Centers which have worked with Aixplorer ultrasound equipment were contacted to share their data. Retrospective statistical analysis used direct and paired receiver operating characteristic and area under the receiver operating characteristic curve (AUROC) analyses, accounting for random effects. Data on both 2D-SWE and liver biopsy were available for 1,134 patients from 13 sites, as well as on successful transient elastography in 665 patients. Most patients had chronic hepatitis C (n = 379), hepatitis B (n = 400), or nonalcoholic fatty liver disease (n = 156). AUROCs of 2D-SWE in patients with hepatitis C, hepatitis B, and nonalcoholic fatty liver disease were 86.3%, 90.6%, and 85.5% for diagnosing significant fibrosis and 92.9%, 95.5%, and 91.7% for diagnosing cirrhosis, respectively. The AUROC of 2D-SWE was 0.022-0.084 (95% confidence interval) larger than the AUROC of transient elastography for diagnosing significant fibrosis (P = 0.001) and 0.003-0.034 for diagnosing cirrhosis (P = 0.022) in all patients. This difference was strongest in hepatitis B patients. Conclusion: 2D-SWE has good to excellent performance for the noninvasive staging of liver fibrosis in patients with hepatitis B; further prospective studies are needed for head-to-head comparison between 2D-SWE and other imaging modalities to establish disease-specific appropriate cutoff points for assessment of fibrosis stage. (Hepatology 2018;67:260-272).

UR - http://www.scopus.com/inward/record.url?scp=85028432780&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85028432780&partnerID=8YFLogxK

U2 - 10.1002/hep.29179

DO - 10.1002/hep.29179

M3 - Article

C2 - 28370257

AN - SCOPUS:85028432780

VL - 67

SP - 260

EP - 272

JO - Hepatology

JF - Hepatology

SN - 0270-9139

IS - 1

ER -